FY2026 EPS Forecast for Perspective Therapeutics Lifted by Analyst

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) – Analysts at Brookline Capital Markets raised their FY2026 EPS estimates for Perspective Therapeutics in a note issued to investors on Tuesday, May 12th. Brookline Capital Markets analyst K. Dolliver now anticipates that the company will post earnings of ($1.23) per share for the year, up from their previous estimate of ($1.27). The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($1.18) per share. Brookline Capital Markets also issued estimates for Perspective Therapeutics’ Q4 2026 earnings at ($0.36) EPS.

Perspective Therapeutics (NYSEAMERICAN:CATX) last released its earnings results on Monday, May 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.04. The firm had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.16 million. Perspective Therapeutics had a negative return on equity of 42.33% and a negative net margin of 17,982.69%.

Several other brokerages have also recently issued reports on CATX. B. Riley Financial raised their price objective on Perspective Therapeutics from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, March 18th. BTIG Research reiterated a “buy” rating and issued a $14.00 target price on shares of Perspective Therapeutics in a research report on Tuesday, March 17th. Truist Financial set a $12.00 price target on shares of Perspective Therapeutics in a report on Tuesday, March 17th. Wedbush reissued an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a research report on Tuesday, May 5th. Finally, Royal Bank Of Canada decreased their price objective on shares of Perspective Therapeutics from $18.00 to $14.00 and set an “outperform” rating for the company in a research note on Tuesday, March 17th. One equities research analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $12.63.

Perspective Therapeutics Stock Up 1.3%

Shares of CATX opened at $3.82 on Thursday. The stock has a 50-day moving average of $4.44 and a two-hundred day moving average of $3.60. Perspective Therapeutics has a one year low of $1.96 and a one year high of $6.16.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Aigen Investment Management LP purchased a new stake in Perspective Therapeutics in the 4th quarter worth approximately $28,000. Russell Investments Group Ltd. lifted its stake in shares of Perspective Therapeutics by 184.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock valued at $29,000 after purchasing an additional 5,475 shares during the period. nVerses Capital LLC purchased a new stake in Perspective Therapeutics during the fourth quarter worth $31,000. AXQ Capital LP boosted its holdings in Perspective Therapeutics by 24.2% during the fourth quarter. AXQ Capital LP now owns 12,749 shares of the company’s stock worth $35,000 after buying an additional 2,481 shares in the last quarter. Finally, Engineers Gate Manager LP acquired a new stake in Perspective Therapeutics during the fourth quarter valued at $35,000. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.